Search

Your search keyword '"Cortot, Alexis"' showing total 574 results

Search Constraints

Start Over You searched for: Author "Cortot, Alexis" Remove constraint Author: "Cortot, Alexis"
574 results on '"Cortot, Alexis"'

Search Results

1. Real-world efficacy of the dabrafenib-trametinib (D-T) combination in BRAF V600E-mutated metastatic non-small cell lung cancer (NSCLC): Results from the IFCT-2004 BLaDE cohort

3. Capmatinib efficacy for METex14 non-small cell lung cancer patients: Results of the IFCT-2104 CAPMATU study

10. Lung cancer trends and tumor characteristic changes over 20 years (2000–2020): Results of three French consecutive nationwide prospective cohorts’ studies

13. Faecalibacterium prausnitzii strain EXL01 boosts efficacy of immune checkpoint inhibitors.

15. Tailoring maintenance chemotherapy upon response to induction chemotherapy as compared with pemetrexed continuation maintenance in advanced non-squamous NSCLC patients: Results of the IFCT-GFPC-1101 multicenter randomized phase III trial

17. Survival and Prognostic Factors After Adrenalectomy for Secondary Malignancy

18. Intergroupe francophone de cancérologie thoracique, Société de pneumologie de langue française, and Société d’imagerie thoracique statement paper on lung cancer screening

20. Circulating tumour cells as a potential biomarker for lung cancer screening: a prospective cohort study

22. Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non–small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study

24. Daily Caffeine Consumption May Increase the Risk of Acute Kidney Injury Related to Platinum-Salt Chemotherapy in Thoracic Cancer Patients: A Translational Study

26. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

30. Real-World Efficacy of the Dabrafenib-Trametinib (D-T) Combination in Braf V600e-Mutated Metastatic Non-Small Cell Lung Cancer (Nsclc): Results from the Ifct-2004 Blade Cohort

31. Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation

32. MET variants with activating N-lobe mutations identified in hereditary papillary renal cell carcinomas still require ligand stimulation

36. Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis

41. Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti–Programmed Cell Death (Ligand)1 and Sotorasib Therapy in KRASG12C-Mutant Lung Cancer

42. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

46. Transforming properties of MET receptor exon 14 skipping can be recapitulated by loss of the CBL ubiquitin ligase binding site

47. MET exon 14 skipping mutation is a hepatocyte growth factor (HGF)‐dependent oncogenic driver in vitro and in humanised HGF knock‐in mice

48. Prolonging lung cancer response to EGFR inhibition by targeting the selective advantage of resistant cells

49. Tepotinib Treatment in Patients With MET Exon 14–Skipping Non–Small Cell Lung Cancer

Catalog

Books, media, physical & digital resources